报价延迟最少15分钟:2026/08/10 09:32 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9326 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.16/-0.64
|
|
企业价值
1.69M
|
| 资产负债 |
|
每股账面净值
2.58
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States. |
